Scarica l'app Stockscreener
5.16
0.77%
-0.04
Dopo l'orario di chiusura:
5.17
0.010
+0.19%
Precedente Chiudi:
$5.20
Aprire:
$5.2
Volume 24 ore:
69,565
Relative Volume:
0.34
Capitalizzazione di mercato:
$104.81M
Reddito:
-
Utile/perdita netta:
$-33.63M
Rapporto P/E:
-2.6982
EPS:
-1.9124
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-2.09%
1M Prestazione:
+8.18%
6M Prestazione:
+19.44%
1 anno Prestazione:
+49.57%
Intervallo 1D:
$5.13
$5.3816
Intervallo di 1 settimana:
$5.13
$5.565
Portata 52W:
$3.06
$5.73
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.16 | 105.62M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
PolyPid (PYPD): Will The November FDA Decision Propel The Stock? - RTTNews
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - vinanet.vn
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction: Shares Close 1.40% Higher in Latest TradingRetail Earnings Report - vinanet.vn
PolyPid | 3: Initial statement of beneficial ownership of securities- Warshavsky Ori - Moomoo
PolyPid | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD - MarketBeat
PolyPid Ltd (PYPD) Stock News Today - TradingKey
PolyPid Ltd. (PYPD) Holds Near $4.75 as Clinical-Stage Biotech Navigates Key Support ZoneCall Resistance - vinanet.vn
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneBollinger Walk - dars.gov.et
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - AlphaStreet
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
PolyPid Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones - TipRanks
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 - tradingview.com
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal - Stock Titan
Press Release: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Moomoo
PYPD Q1 2026 Earnings: Narrower Loss of -$0.35 Beats Consensus by 20.81%Buyback Announcement Report - vinanet.vn
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PYPD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD) - TradingView
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - The Manila Times
PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 - Quiver Quantitative
PolyPid Q1 2026 Earnings: EPS Beats Estimates as Company Advances PipelineEarnings Manipulation Risk - vinanet.vn
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review By Investing.com - Investing.com South Africa
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review - Investing.com Nigeria
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ - GlobeNewswire
PolyPid (PYPD) Surges 8.8%: Momentum Builds Above Key Support LevelButterfly Setup - vinanet.vn
PolyPid Ltd. Revenue Breakdown – NASDAQ:PYPD - TradingView
PolyPid Ltd (PYPD) Balance Sheet - TradingKey
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYPD|PolyPid Ltd|Price:3.950|Chg%:+0.050 - TradingKey
PYPD|PolyPid Ltd|Price:4.290|Chg%:-0.080 - TradingKey
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):